Manufacturing genetically modified T cells for clinical trials.
- Published in:
- Cancer Gene Therapy, 2015, v. 22, n. 2, p. 67, doi. 10.1038/cgt.2014.71
- By:
- Publication type:
- Article
Works matching IS 09291903 AND DT 2015 AND VI 22 AND IP 2
Results: 7
1
2
Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells.
- Published in:
- Cancer Gene Therapy, 2015, v. 22, n. 2, p. 79, doi. 10.1038/cgt.2015.5
- By:
- Publication type:
- Article
3
Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.
- Published in:
- Cancer Gene Therapy, 2015, v. 22, n. 2, p. 85, doi. 10.1038/cgt.2014.81
- By:
- Publication type:
- Article
4
Genetically engineered lymphocytes and adoptive cell therapy: cancer immunotherapy's smart bombs.
- Published in:
- Cancer Gene Therapy, 2015, v. 22, n. 2, p. 63, doi. 10.1038/cgt.2015.1
- By:
- Publication type:
- Article
5
Moving from tinkering in the garage to assembly line production: the manufacture of genetically modified T cells expressing chimeric antigen receptors (CARs) comes on line.
- Published in:
- Cancer Gene Therapy, 2015, v. 22, n. 2, p. 64, doi. 10.1038/cgt.2014.70
- By:
- Publication type:
- Article
6
Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.
- Published in:
- Cancer Gene Therapy, 2015, v. 22, n. 2, p. 95, doi. 10.1038/cgt.2014.69
- By:
- Publication type:
- Article
7
Towards a commercial process for the manufacture of genetically modified T cells for therapy.
- Published in:
- Cancer Gene Therapy, 2015, v. 22, n. 2, p. 72, doi. 10.1038/cgt.2014.78
- By:
- Publication type:
- Article